This provider's $9.1M in total Medicare payments ranks in the 98th percentile of Ophthalmology providers nationally.
Medicare payments to this provider grew 86% from 2014 to 2023.
AI-generated analysis based on Medicare payment data.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2014 | $408.99 | $150.42 | 2.72x | $258.57 | $617.2K | 6.8K | 3.5K |
| 2015 | $403.64 | $149.74 | 2.70x | $253.90 | $732.0K | 6.8K | 3.5K |
| 2016 | $655.98 | $192.75 | 3.40x | $463.23 | $842.0K | 7.4K | 4.0K |
| 2017 | $458.22 | $138.17 | 3.32x | $320.05 | $1.0M | 8.2K | 4.3K |
| 2018 | $463.68 | $140.16 | 3.31x | $323.52 | $772.9K | 7.7K | 3.7K |
| 2019 | $495.01 | $143.33 | 3.45x | $351.68 | $906.9K | 7.9K | 3.6K |
| 2020 | $413.14 | $161.82 | 2.55x | $251.32 | $892.3K | 7.0K | 3.0K |
| 2021 | $384.83 | $176.80 | 2.18x | $208.03 | $1.0M | 7.2K | 3.0K |
| 2022 | $389.08 | $130.52 | 2.98x | $258.56 | $1.2M | 7.5K | 3.2K |
| 2023 | $945.77 | $237.35 | 3.98x | $708.42 | $1.1M | 6.8K | 3.2K |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 4.7K | $3.4M | $728.98 | 2.71x |
| J2778 | Injection, ranibizumab, 0.1 mg | 5.6K | $1.5M | $274.61 | 1.86x |
| 67028 | Injection of drug into eye | 14.0K | $1.3M | $89.75 | 5.02x |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | 10.0K | $870.8K | $86.74 | 2.14x |
| 92134 | Diagnostic imaging of retina | 18.9K | $575.3K | $30.38 | 2.87x |
| 92012 | Eye and medical examination for diagnosis and treatment, established patient | 4.6K | $289.1K | $63.43 | 2.08x |
| J3590 | Unclassified biologics | 127 | $267.7K | $2.1K | 3.81x |
| 92250 | Photography of the retina | 5.1K | $227.0K | $44.11 | 2.74x |
| 92004 | Eye and medical examination for diagnosis and treatment, new patient, 1 or more visits | 2.0K | $208.7K | $106.20 | 2.11x |
| J9035 | Injection, bevacizumab, 10 mg | 2.3K | $130.4K | $56.02 | 2.58x |
| 92235 | Examination of retinal blood vessels by ophthalmoscope | 927 | $72.7K | $78.38 | 3.59x |
| 67145 | Preventive retinal detachment treatment by heat or laser, 1 or more sessions | 100 | $31.9K | $319.25 | 2.68x |
| J7999 | Compounded drug, not otherwise classified | 432 | $31.5K | $72.99 | 4.55x |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 137 | $29.7K | $216.69 | 3.88x |
| 67228 | Laser destruction of leaking retinal blood vessels, 1 or more sessions | 105 | $26.7K | $253.97 | 5.67x |
| 92225 | Examination of eye by ophthalmoscope with retinal drawing | 1.2K | $24.8K | $20.17 | 2.00x |
| 92226 | Examination of eye by ophthalmoscope with retinal drawing | 1.3K | $22.0K | $17.42 | 2.34x |
| 67221 | Destruction of vascular growth between retina and sclera | 91 | $19.7K | $216.32 | 3.65x |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | 127 | $19.5K | $153.74 | 2.60x |
| 67210 | Laser destruction of retinal growth, 1 or more sessions | 42 | $15.8K | $377.33 | 3.18x |
This provider submits charges 2.88 times higher than what Medicare actually pays.
A markup ratio of 2.88x means for every $100 Medicare pays, this provider initially charges $288. This is higher than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Other Ophthalmology providers in TX for peer comparison.
| Provider | Location | Total Payments | Status |
|---|---|---|---|
| Jason Ysasaga, M.D. | Amarillo, TX | $61.5M | ✓ Clear |
| Harshivinderjit Bains, MD | Tyler, TX | $53.9M | ✓ Clear |
| Ryan Rush, MD | Amarillo, TX | $53.6M | ✓ Clear |
| Tien Wong, M.D. | Houston, TX | $51.2M | ✓ Clear |
| Thomas Bochow, M.D., M.P.H. | Tyler, TX | $49.4M | ✓ Clear |
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data